Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies

Abstract

Infections are a common complication in patients with hematological malignancies, especially during neutropenia. Recently, an increase in multidrug-resistant gram-negative pathogens has been observed in the etiology of infectious complications, including carbapenem-resistant Enterobacteriaceae. However, therapeutic options for treatment of these infections are limited. The review represents treatment options for infections caused by carbapenem-resistant Enterobacteriaceae, including the use of reserve drugs such as polymyxin, carbapenems, tigecycline, as well as a new antibiotic-ceftazidime-avibactam, which contains a new β-lactamase inhibitor with unique properties.